NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $117.16 +0.57 (+0.48%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Incyte Stock (NASDAQ:INCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Incyte alerts:Sign Up Key Stats Today's Range$114.74▼$118.4950-Day Range$108.62▼$129.7252-Week Range$88.20▼$132.60Volume588,344 shsAverage Volume1.72 million shsMarket CapitalizationN/AP/E Ratio14.94Dividend YieldN/APrice Target$131.43Consensus RatingHold Company Overview Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions. Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms. Incyte also markets Monjuvi in the United States and Minjuvi in other markets with its partner MorphoSys for certain patients with diffuse large B-cell lymphoma. Founded in 1991, Incyte is headquartered in Wilmington, Delaware, and serves markets in the United States and internationally through its commercial operations and partnerships. The company also maintains a research and development pipeline spanning hematology, oncology, dermatology and other immune-mediated diseases. Incyte is led by Chief Executive Officer Hervé Hoppenot, who has served in that role since 2014.AI Generated. May Contain Errors. Read More Incyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreINCY MarketRank™: 3.95212765957 of 5 starsIncyte scored higher than 79% of companies evaluated by MarketBeat, and ranked 111th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 12 buy ratings, 12 hold ratings, and 1 sell rating.Upside PotentialIncyte has a consensus price target of $131.43, representing about 11.4% upside from its current price of $118.00.Amount of Analyst CoverageIncyte has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth283.25% Earnings GrowthEarnings for Incyte are expected to grow by 283.25% in the coming year, from $1.97 to $7.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 15.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 15.08, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.87.Read more about Incyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.90% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 5.32.Change versus previous monthShort interest in Incyte has recently increased by 0.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.28 News SentimentIncyte has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Incyte this week, compared to 8 articles on an average week.Search Interest19 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat Follows8 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,659,208.00 in company stock.Percentage Held by Insiders16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCY Stock News HeadlinesAdagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer1 hour ago | markets.businessinsider.comIncyte (INCY) reports Q3: everything you need to know ahead of earnings1 hour ago | finance.yahoo.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 28 at 1:00 AM | Weiss Ratings (Ad)Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs - SlideshowOctober 27 at 8:01 AM | seekingalpha.comIncyte: KRAS G12D PDAC Data Underscore Undervalued Opportunity as Buy Rating and $152 Price Target Are ReiteratedOctober 27 at 7:31 AM | tipranks.comIncyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs TranscriptOctober 27 at 6:00 AM | seekingalpha.comIncyte Announces New Results For INCB161734 And INCA33890 In Gastrointestinal Cancer Portfolio At ESMO 2026October 27 at 4:15 AM | marketscreener.comMBalanced View on Incyte: Promising Oncology Pipeline Offset by Long-Term Execution and Timing Risks Justifying Hold RatingOctober 26 at 9:31 PM | tipranks.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $98.77 at the beginning of 2026. Since then, INCY stock has increased by 19.5% and is now trading at $117.9980. How were Incyte's earnings last quarter? Incyte Corporation (NASDAQ:INCY) posted its earnings results on Tuesday, July, 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.94. Incyte's quarterly revenue was up 37.7% on a year-over-year basis. Read the conference call transcript. Who are Incyte's major shareholders? Incyte's top institutional shareholders include Robeco Institutional Asset Management B.V. (1.09%), Assenagon Asset Management S.A. (0.06%), Crossmark Global Holdings Inc. (0.06%) and Asset Management One Co. Ltd. (0.05%). Insiders that own company stock include Pablo J Cagnoni, Mohamed Khairie Issa, Steven H Stein, Patrick A Mayes, Barry P Flannelly, Jonathan Elliott Dickinson, Vijay K Iyengar, Lee Heeson, Michael James Morrissey, Sheila A Denton and Thomas Tray. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Alibaba Group (BABA) and Tesla (TSLA). Company Calendar Last Earnings7/28/2026Today10/28/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, INCY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,844Year Founded1991Price Target and Rating Average Price Target for Incyte$131.43 High Price Target$157.00 Low Price Target$90.00 Potential Upside/Downside+11.4%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio15.08 Forward P/E Ratio59.90 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree Float169,861,000Market CapN/A OptionableOptionable BetaN/A Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:INCY) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
